Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

about

Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.Application of Immuno-PET in Antibody-Drug Conjugate Development

P2860

Q55094448-84E80A9C-AFB2-4557-8BF1-84CA0F1A8656 Q58132996-54F7F73E-59E0-4054-9E7B-AB4428C70C07

P2860

Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

Item

http://www.wikidata.org/entity/Q47102763

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Understanding CD30 biology and ...... nsight into future directions.

@en

Understanding CD30 biology and ...... nsight into future directions.

@nl

type

Item

label

Understanding CD30 biology and ...... nsight into future directions.

@en

Understanding CD30 biology and ...... nsight into future directions.

@nl

prefLabel

Understanding CD30 biology and ...... nsight into future directions.

@en

Understanding CD30 biology and ...... nsight into future directions.

@nl

P1476

Understanding CD30 biology and ...... nsight into future directions.

@en

P2093

A L Feldman

http://www.w3.org/2001/XMLSchema#string

C A van der Weyden

http://www.w3.org/2001/XMLSchema#string

H M Prince

http://www.w3.org/2001/XMLSchema#string

J Whisstock

http://www.w3.org/2001/XMLSchema#string

S A Pileri

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF

Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3

Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival

Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1

Solution of the structure of the TNF-TNFR2 complex

MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival

Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family

Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay

Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population

P2888

bcj.2017.85

P304

e603

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1038/BCJ.2017.85

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28885612

http://www.w3.org/2001/XMLSchema#string

P921

non-Hodgkin lymphoma

Hodgkin's lymphoma

cell surface receptor

P932

5709754

http://www.w3.org/2001/XMLSchema#string

Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

about

P2860

P2860

Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932